News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
India is at a key inflexion point of not just ‘Heal in India’ through its vibrant medical value tourism, but also ‘Heal by India’, where our medical professionals can be used to serve not just our country but at the global level.
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
To address the preventive & primary healthcare delivery gaps in India
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Subscribe To Our Newsletter & Stay Updated
